单株抗体的全球市场预测(2022年～2027年)

全球单株抗体的市场规模在2020年估算为1,307亿5,800万美金，7.99％的年复合成长率增长，到2027年达到2,238亿8,500万美元。

本报告提供全球单株抗体市场相关调查，提供市场规模和预测，COVID-19影响，市场促进因素及课题，市场趋势，各市场区隔的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 简介

• 市场概要
• COVID-19影响
• 市场定义
• 市场区隔

第2章 调查手法

• 调查资料
• 前提条件

第3章 摘要整理

• 调查的重点

第4章 市场动态

• 推动市场要素
• 阻碍市场要素
• 波特的五力分析
  • 供给企业谈判力
  • 买方议价能力
  • 新加入厂商者的威胁
  • 替代品的威胁
  • 竞争企业间的敌对关係
• 产业的价值链分析

第5章 单株抗体市场:各适应症

• 简介
• 发炎性疾病
• 癌症
• 微生物病
• 其他

第6章 单株抗体市场:各原料

• 简介
• 人体化
• 人
• 嵌合体
• 老鼠

第7章 单株抗体市场:各用途

• 简介
• 诊断
• 治疗
• 其他

第8章 单株抗体市场:各终端用户

• 简介
• 医院·诊疗所
• 研究

第9章 单株抗体市场:各地区

• 简介
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 南美
  • 巴西
  • 阿根廷
  • 其他
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他
• 中东·非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他
• 亚太地区
  • 中国
  • 日本
  • 韩国
  • 印度
  • 泰国
  • 台湾
  • 其他

第10章 竞争环境与分析

• 主要企业策略分析
• 新兴企业与市场的有利性
• 合併，收购，契约，合作
• 供应商的竞争矩阵

第11章 企业简介

• Eli Lilly and Company
• AbbVie, Inc.
• Novartis AG
• Bristol Myers Squibb
• F.Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• Amgen Inc.
• Merck & Co. Inc.
• AstraZeneca PLC

The monoclonal antibodies market is projected to grow at a CAGR of 7.99% to reach US$223.885 billion by 2027, from US$130.758 billion in 2020.

The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule is designed to enhance the body's natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the symptom severity.

Increased demand for monoclonal antibodies

According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, a large number of monoclonal antibodies' clinical trials took place in order to develop novel drug therapy as well a wide range of product approvals were made for emergency use in COVID-19 treatment.

With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibodies therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.

Key Developments

• In April 2020, Merck announced the launch of the biosimilar to trastuzumab (Herceptin), which is widely recommended for the treatment of metastatic breast cancer and metastatic gastric cancer. The trastuzumab biosimilar is known as trastuzumab-dttb (Ontruzant), in the United States. The doses are available in both 150-mg single-dose vials and 420-mg multiple-dose vials. In January 2019, the FDA approved Trastuzumab-dttb. Moreover, in March 2020, FDA subsequently approved a 420-mg multi-dose of trastuzumab-bttb. The US launch was made as a part of a development and commercialization agreement with Samsung Bioepis.
• In May 2022, Swiss multinational Roche Pharma announced the launch of the world's first fixed dose combination of two monoclonal antibodies, PHESGO, in oncology for the treatment of HER-2-positive breast cancer in India. The company combined the injections of Perjeta (pertuzumab) and Herceptin (trastuzumab). The dose will be used as intravenous (IV) chemotherapy. They will be useful in the treatment of early and metastatic HER2-positive breast cancer. The dose combination has been approved in over 100 countries worldwide. The company has quoted the drug's price as 20% less than individual meditations.
• In February 2019, China National Medical Products Administration (NMPA) approved Henlius's first product, HLX01 (rituximab injection). The dose will be used for the treatment of adult patients in three indications such as- i) relapsed or refractory, follicle lymphoma, ii) previously untreated stages III-IV follicular, non-Hodgkin's lymphoma, and iii) CD20-positive. HLX01 was China's first approved product which was the first independently researched and developed mAb drug in China.

North America is expected to hold a significant share during the anticipated period

North American countries have well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and also putting the population at a high risk of being infected with cancer. According to a study by American Cancer Society researchers in 2019, there were at least 42% of newly diagnosed cancers in the US - about 740,000 cases in 2019 were potentially avoidable. The study also said that out of the newly diagnosed cancer patient 19% of all cancers are caused by smoking and 18% are caused due to lack of physical activity, excess alcohol, and junk food consumption, which leads to excess body weight and poor nutrition. Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. For example, in October 2022, Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

COVID-19 Insights

During the pandemic, when there wasn't a specific treatment for COVID-19, monoclonal antibodies were widely used in the treatment of COVID-19 patients. Monoclonal antibodies therapy prevented hospitalization, reduced viral loads, and lessened symptom severity of the virus. FDA granted several monoclonal antibody therapies Emergency Use Authorization (EUA) for the treatment of COVID-19. Moreover, in 2021, the potential application of monoclonal antibody therapy was extended by FDA for the preventive use for those who were at risk due to a confirmed exposure to the virus. The decision was based on the basis of a large clinical trial that found that monoclonal antibodies prevented the symptoms during the interaction of COVID positive family members with the other household members. Monoclonal antibody therapy was done through intravenous (IV) infusion during the pandemic.

Market Segmentation:

• By Indication

Inflammatory Disease

Cancer

Microbial Disease

Others

• By Source

Humanized

Human

Chimeric

Murine

• By Application

Diagnostic

Therapeutic

Others

• By End-User

Hospitals & Clinics

Research Laboratories

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• United Kingdom
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• China
• Japan
• South Korea
• India
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. COVID-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. MONOCLONAL ANTIBODY MARKET, BY INDICATION

• 5.1. Introduction
• 5.2. Inflammatory Disease
• 5.3. Cancer
• 5.4. Microbial Disease
• 5.5. Others

6. MONOCLONAL ANTIBODY MARKET, BY SOURCE

• 6.1. Introduction
• 6.2. Humanized
• 6.3. Human
• 6.4. Chimeric
• 6.5. Murine

7. MONOCLONAL ANTIBODY MARKET, BY Application

• 7.1. Introduction
• 7.2. Diagnostic
• 7.3. Therapeutic
• 7.4. Others

8. MONOCLONAL ANTIBODY MARKET, BY END-USER

• 8.1. Introduction
• 8.2. Hospitals & Clinic
• 8.3. Research Labourites

9. MONOCLONAL ANTIBODY MARKET, BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. Japan
  • 9.6.3. South Korea
  • 9.6.4. India
  • 9.6.5. Thailand
  • 9.6.6. Taiwan
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Emerging Players and Market Lucrativeness
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

• 11.1. Eli Lilly and Company
• 11.2. AbbVie, Inc.
• 11.3. Novartis AG
• 11.4. Bristol Myers Squibb
• 11.5. F.Hoffmann-La Roche Ltd
• 11.6. Johnson & Johnson Services, Inc.
• 11.7. Amgen Inc.
• 11.8. Merck & Co. Inc.
• 11.9. AstraZeneca PLC